Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. - Wikidata - awgldk - TriplyDB

Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements.

Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements.

http://www.wikidata.org/entity/Q31159878

about

The clinical use of structural MRI in Alzheimer disease Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes Proton MRS in mild cognitive impairment.Magnetic resonance spectroscopy in Alzheimer's disease.A longitudinal study of cognition, proton MR spectroscopy and synaptic and neuronal pathology in aging wild-type and AβPPswe-PS1dE9 mice Magnetic resonance spectroscopy in common dementias Clinical proton MR spectroscopy in central nervous system disorders Advances in high-field magnetic resonance spectroscopy in Alzheimer's disease Various MRS application tools for Alzheimer disease and mild cognitive impairment.In vivo imaging of neuroinflammation in schizophrenia Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis.Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study A review of neuroimaging biomarkers of Alzheimer's disease.Early Alzheimer's disease neuropathology detected by proton MR spectroscopy.Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy.Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM Rare copy number deletions predict individual variation in human brain metabolite concentrations in individuals with alcohol use disorders.Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults.Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study.In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice Effects of Methyl Mercury Chloride on Rat Hippocampus Structure.The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy.APOE genotype and age modifies the correlation between cognitive status and metabolites from hippocampus by a 2D (1)H-MRS in non-demented elders MRS in early and presymptomatic carriers of a novel octapeptide repeat insertion in the prion protein gene.Measuring mitochondrial metabolism in rat brain in vivo using MR Spectroscopy of hyperpolarized [2-¹³C]pyruvate.MRI and MRS predictors of mild cognitive impairment in a population-based sample.Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes.Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study.Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease.Metabolite investigation in both anterior and posterior cingulate gyri in Alzheimer's disease spectrum using 3-tesla MR spectroscopy.The use of hyperpolarized carbon-13 magnetic resonance for molecular imaging.Neuroimaging in human prion disease: Searching in the mist.Posterior cingulate γ-aminobutyric acid and glutamate/glutamine are reduced in amnestic mild cognitive impairment and are unrelated to amyloid deposition and apolipoprotein E genotype.1H-MRS metabolites and rate of β-amyloid accumulation on serial PET in clinically normal adults.Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.Glutamine and Glutamate Complex, as Measured by Functional Magnetic Resonance Spectroscopy, Alters During Face-Name Association Task in Patients with Mild Cognitive Impairment and Alzheimer's Disease.Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study.Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET.

P2860

Q24609648-0442DA03-953C-49BF-9D3A-B03181166DDE Q26797413-E57864AC-A482-4A59-B292-9F7FADC8DD8B Q30606675-FC9E0A91-967A-40BB-A4E7-94A5518E9DCB Q30630699-E135A290-D2F7-4C0B-A6CA-C2B676470833 Q30635401-DFAEBB2D-C0FD-4A80-B2EE-090CFB895E0C Q30660402-C8A657FE-1A58-41BF-8344-4321C579AD6F Q30764446-60902FCA-FFC8-4A1E-BA86-E231CD130380 Q30770751-1926D21A-06FD-49DA-B81F-ABF806F78D24 Q30803093-0A3F4CA2-1DA6-4F8F-87A6-A69A2A71F5B0 Q30966978-9DDCFE1E-F121-4787-9C37-1E35601B9C5D Q30996805-D55356B8-DFBD-446C-9494-2D9784FD7339 Q33963735-FE77381F-ED53-4C1D-A9D1-D4488C600BE2 Q34125535-1C54E016-0F51-477B-9BDD-F32F02438333 Q34247831-1090176E-D347-40A6-950A-1B76B896C1E7 Q34571189-752E7B3A-5910-4DD0-AC3D-3631D2B1FEFA Q34614543-F7B5DF8D-573C-430E-ADAB-17B74DC44CF2 Q34951012-D52ED6FD-D281-40B5-9387-511B15CB25F6 Q34992526-8C2A5A90-0484-4370-B8E6-6BD68F3CF8EC Q35182074-BE915ACA-3A87-4A49-B97F-8817D8527B6C Q35210272-3FF445AB-3A81-4221-9B15-CFCA0BBAC327 Q35319467-D68243B4-012A-4F81-94D1-4123CCBC1AA2 Q35565488-0B077E83-CE14-40B5-9957-48D1DF947A1D Q35770087-29076AF8-B58F-41A6-8582-4ECAC08A7078 Q35939212-89D6F175-E971-406C-B060-921939015926 Q36083501-C3C1F214-3690-4A1D-868B-01BB61FAF379 Q36345364-322007B0-F962-476E-9A6C-86EE60FE1F15 Q37053780-C8328C75-D91C-42B9-AFAD-874A492AC6AE Q37163305-38279D83-6B01-41EE-A38C-20C34C268D96 Q37345411-0E998DC7-5E0D-46E4-8E13-1B61FDE2F967 Q37381065-8DED912D-F136-4502-A82A-C461E1A843BA Q37876426-5416CA9C-FF40-4744-8218-3C8694CA5F93 Q38461379-20E03F89-5340-48FA-93F7-5D5F1AEC17B1 Q38947519-8F9A6F05-44D4-463C-B929-6EA4F563A1CF Q41127706-BB45D000-29B1-4CE7-8008-8FC6FB78188A Q41151004-96C97C0D-4C14-4C2F-B1AE-84EED06BFEBB Q42665050-3EBF9B78-D572-4A1B-80B6-B6702BD0B1A5 Q43252674-D12D82C2-D25B-48D4-84AB-0200E4BF1522 Q44269590-3C90C35B-E7BD-4BE1-990A-DF77A17F99B7 Q44937365-F26B1A84-3E8B-4D16-B176-A4443073C361 Q45732943-C5B2827B-6A9E-42C0-9A41-C1B8864C0902

P2860

Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements.

http://www.wikidata.org/entity/Q31159878

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Alzheimer disease: postmortem ...... scopy metabolite measurements.

@ast

Alzheimer disease: postmortem ...... scopy metabolite measurements.

@en

type

label

Alzheimer disease: postmortem ...... scopy metabolite measurements.

@ast

Alzheimer disease: postmortem ...... scopy metabolite measurements.

@en

prefLabel

Alzheimer disease: postmortem ...... scopy metabolite measurements.

@ast

Alzheimer disease: postmortem ...... scopy metabolite measurements.

@en

P1433

Q31159878-9ED2C186-02FF-4E25-836B-B8732DD5D0E1

P1476

Q31159878-CBFCF800-296E-4561-BE9F-6B8A34D0F7A9

P2093

Q31159878-512C5B34-E5A5-459D-A65E-E626852EB9C6

Q31159878-8492982A-6B32-4941-8AD2-0F4A6638F5D6

Q31159878-A86948D8-6D17-4E29-B419-D9081A03C0EE

Q31159878-B8987D50-FFD7-4DC3-8FCB-CB8E9BFB32C6

Q31159878-FD7EA6C3-0C5F-4E57-9C11-23D868945AFD

P2860

Q31159878-075E757E-AB2A-4BE7-BCAD-D613D211B5F0

Q31159878-0AEFD66C-A3E0-4533-ACF4-8E5865983AE6

Q31159878-1506CCF4-4164-4B29-B123-84ECFA739449

Q31159878-1E5CA6B1-BF27-459C-8AB2-131E32BD86E6

Q31159878-1F918501-BC81-42AA-9142-1AF191292131

Q31159878-272229D1-3A7C-4154-9280-1355E927F80E

Q31159878-28091C51-638D-412B-9EAA-906F4CD26EAD

Q31159878-2931C6B9-3EA4-4B6F-9C9B-D21B83F1DA7B

Q31159878-2B7E9920-6158-4259-9C39-E947C1ACC3A4

Q31159878-343EAEAE-1B26-401E-AAF3-28A907DEEEB1

P304

Q31159878-6C218A32-3695-49BE-9BC4-5208EC86FB13

P31

Q31159878-996E83E3-C1B8-484D-A8B9-25D2CB4E1170

P356

Q31159878-9163FFEC-FF8B-4EFA-81F9-8406BBCB6E95

P407

Q31159878-FA50400F-3216-4C65-A0C7-EED32EA2DDAC

P433

Q31159878-FEB801BD-7602-41D1-8BD2-AFC709516F0E

P478

Q31159878-7939B8DA-6863-4FFF-9EF3-E8E643AD1275

P50

Q31159878-0AEF4D66-2322-4629-8F98-16E7382C48EB

Q31159878-1CA467B3-FD0E-4BFB-BEF2-E6E85D44A884

Q31159878-65A68D67-EFFC-44BD-A0BE-12048ADAFDBC

Q31159878-F30597CD-4BA5-450F-91C1-7FC2200C1BCC

Q31159878-FEB8956E-1435-4EE6-A3B6-FB498F560FDD

P577

Q31159878-75EB85BE-4A90-41FD-B756-F905F3391E0C

P5875

Q31159878-5E4CDC77-AC8A-49D9-9ACA-B8DCBBFF36D4

P698

Q31159878-1EBE6FDA-8560-4AFF-9D3D-C53C1945DE75

P921

Q31159878-37D6A62C-4E2F-42D0-B598-19884186329D

P932

Q31159878-0E412857-2BD8-4E3F-9C5D-3C36173ED98B

P356

RADIOL.2481071590

P1433

P1476

Alzheimer disease: postmortem ...... scopy metabolite measurements.

@en

P2093

Bradley F Boeve

http://www.w3.org/2001/XMLSchema#string

Jennifer L Whitwell

http://www.w3.org/2001/XMLSchema#string

Joseph E Parisi

http://www.w3.org/2001/XMLSchema#string

Keith A Josephs

http://www.w3.org/2001/XMLSchema#string

Stephen D Weigand

http://www.w3.org/2001/XMLSchema#string

P2860

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Neuropathological stageing of Alzheimer-related changes

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

What's wrong with Bonferroni adjustments.

Mild cognitive impairment as a diagnostic entity

Biomarkers of Alzheimer disease.

Magnetic resonance spectroscopy in AD.

Neuroimaging in Alzheimer disease: an evidence-based review.

P304

210-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1148/RADIOL.2481071590

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

248

http://www.w3.org/2001/XMLSchema#string

P50

Dennis W. Dickson

Ronald C. Petersen

David S Knopman

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5288757

http://www.w3.org/2001/XMLSchema#string

P698

18566174

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2735577

http://www.w3.org/2001/XMLSchema#string